File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease

TitleAspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease
Authors
Issue Date2007
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amj
Citation
American Journal Of Medicine, 2007, v. 120 n. 7, p. 631-635 How to Cite?
AbstractPurpose: We sought to determine the clinical significance of aspirin resistance measured by a point-of-care assay in stable patients with coronary artery disease (CAD). Methods: We used the VerifyNow Aspirin (Accumetrics Inc, San Diego, Calif) to determine aspirin responsiveness of 468 stable CAD patients on aspirin 80 to 325 mg daily for ≥4 weeks. Aspirin resistance was defined as an Aspirin Reaction Unit ≥550. The primary outcome was the composite of cardiovascular death, myocardial infarction (MI), unstable angina requiring hospitalization, stroke, and transient ischemic attack. Results: Aspirin resistance was noted in 128 (27.4%) patients. After a mean follow-up of 379 ± 200 days, patients with aspirin resistance were at increased risk of the composite outcome compared to patients who were aspirin-sensitive (15.6% vs 5.3%, hazard ratio [HR] 3.12, 95% confidence intervals [CI], 1.65-5.91, P < .001). Cox proportional hazard regression modeling identified aspirin resistance, diabetes, prior MI, and a low hemoglobin to be independently associated with major adverse long-term outcomes (HR for aspirin resistance 2.46, 95% CI, 1.27-4.76, P = .007). Conclusions: Aspirin resistance, defined by an aggregation-based rapid platelet function assay, is associated with an increased risk of adverse clinical outcomes in stable patients with CAD. © 2007 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/76952
ISSN
2015 Impact Factor: 5.61
2015 SCImago Journal Rankings: 2.023
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChen, WHen_HK
dc.contributor.authorCheng, Xen_HK
dc.contributor.authorLee, PYen_HK
dc.contributor.authorNg, Wen_HK
dc.contributor.authorKwok, JYYen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorLau, CPen_HK
dc.date.accessioned2010-09-06T07:26:41Z-
dc.date.available2010-09-06T07:26:41Z-
dc.date.issued2007en_HK
dc.identifier.citationAmerican Journal Of Medicine, 2007, v. 120 n. 7, p. 631-635en_HK
dc.identifier.issn0002-9343en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76952-
dc.description.abstractPurpose: We sought to determine the clinical significance of aspirin resistance measured by a point-of-care assay in stable patients with coronary artery disease (CAD). Methods: We used the VerifyNow Aspirin (Accumetrics Inc, San Diego, Calif) to determine aspirin responsiveness of 468 stable CAD patients on aspirin 80 to 325 mg daily for ≥4 weeks. Aspirin resistance was defined as an Aspirin Reaction Unit ≥550. The primary outcome was the composite of cardiovascular death, myocardial infarction (MI), unstable angina requiring hospitalization, stroke, and transient ischemic attack. Results: Aspirin resistance was noted in 128 (27.4%) patients. After a mean follow-up of 379 ± 200 days, patients with aspirin resistance were at increased risk of the composite outcome compared to patients who were aspirin-sensitive (15.6% vs 5.3%, hazard ratio [HR] 3.12, 95% confidence intervals [CI], 1.65-5.91, P < .001). Cox proportional hazard regression modeling identified aspirin resistance, diabetes, prior MI, and a low hemoglobin to be independently associated with major adverse long-term outcomes (HR for aspirin resistance 2.46, 95% CI, 1.27-4.76, P = .007). Conclusions: Aspirin resistance, defined by an aggregation-based rapid platelet function assay, is associated with an increased risk of adverse clinical outcomes in stable patients with CAD. © 2007 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amjen_HK
dc.relation.ispartofAmerican Journal of Medicineen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAspirin - therapeutic useen_HK
dc.subject.meshCoronary Artery Disease - drug therapy - mortalityen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDrug Resistanceen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPlatelet Aggregation Inhibitors - therapeutic useen_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleAspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0002-9343&volume=120&issue=7&spage=631&epage=5&date=2007&atitle=Aspirin+resistance+and+adverse+clinical+events+in+patients+with+coronary+artery+disease.en_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.amjmed.2006.10.021en_HK
dc.identifier.pmid17602938-
dc.identifier.scopuseid_2-s2.0-34250816849en_HK
dc.identifier.hkuros136216en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34250816849&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume120en_HK
dc.identifier.issue7en_HK
dc.identifier.spage631en_HK
dc.identifier.epage635en_HK
dc.identifier.isiWOS:000247672100016-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChen, WH=7409637978en_HK
dc.identifier.scopusauthoridCheng, X=37044433500en_HK
dc.identifier.scopusauthoridLee, PY=8933949600en_HK
dc.identifier.scopusauthoridNg, W=7401613562en_HK
dc.identifier.scopusauthoridKwok, JYY=8933949800en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats